Tandem Diabetes Care Shares Spike After Wells Fargo Upgrade and Strong Q1 Results
Tandem Diabetes Care's stock surged 14.1% in mid-day trading after Wells Fargo upgraded the company to Overweight from Equal Weight and lifted its price target to $27 from $21. The firm highlighted Tandem's rapidly expanding pharmacy channel as a material, underappreciated long-term opportunity. Management disclosed progress rebuilding formulary co…